Osteosarcoma in Children: Not Only Chemotherapy
Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year survival rate is about 67% for patients with loca...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/9/923 |
| _version_ | 1797517641732063232 |
|---|---|
| author | Maura Argenziano Chiara Tortora Elvira Pota Alessandra Di Paola Martina Di Martino Caterina Di Leva Daniela Di Pinto Francesca Rossi |
| author_facet | Maura Argenziano Chiara Tortora Elvira Pota Alessandra Di Paola Martina Di Martino Caterina Di Leva Daniela Di Pinto Francesca Rossi |
| author_sort | Maura Argenziano |
| collection | DOAJ |
| description | Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year survival rate is about 67% for patients with localized OS, while it remains at 20% in case of metastases. The standard therapy for OS patients is represented by neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. The most used chemotherapy regimen for children is the combination of high-dose methotrexate, doxorubicin, and cisplatin. Considered that the necessary administration of high-dose chemotherapy is responsible for a lot of acute and chronic side effects, the identification of novel therapeutic strategies to ameliorate OS outcome and the patients’ life expectancy is necessary. In this review we provide an overview on new possible innovative therapeutic strategies in OS. |
| first_indexed | 2024-03-10T07:19:22Z |
| format | Article |
| id | doaj.art-78f0bb1d10f54b3a9c0433950b13b2d0 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T07:19:22Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-78f0bb1d10f54b3a9c0433950b13b2d02023-11-22T14:45:32ZengMDPI AGPharmaceuticals1424-82472021-09-0114992310.3390/ph14090923Osteosarcoma in Children: Not Only ChemotherapyMaura Argenziano0Chiara Tortora1Elvira Pota2Alessandra Di Paola3Martina Di Martino4Caterina Di Leva5Daniela Di Pinto6Francesca Rossi7Department of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyOsteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year survival rate is about 67% for patients with localized OS, while it remains at 20% in case of metastases. The standard therapy for OS patients is represented by neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. The most used chemotherapy regimen for children is the combination of high-dose methotrexate, doxorubicin, and cisplatin. Considered that the necessary administration of high-dose chemotherapy is responsible for a lot of acute and chronic side effects, the identification of novel therapeutic strategies to ameliorate OS outcome and the patients’ life expectancy is necessary. In this review we provide an overview on new possible innovative therapeutic strategies in OS.https://www.mdpi.com/1424-8247/14/9/923osteosarcomachemoresistancetherapyproteasome inhibitorsimmunotherapyiron chelation |
| spellingShingle | Maura Argenziano Chiara Tortora Elvira Pota Alessandra Di Paola Martina Di Martino Caterina Di Leva Daniela Di Pinto Francesca Rossi Osteosarcoma in Children: Not Only Chemotherapy Pharmaceuticals osteosarcoma chemoresistance therapy proteasome inhibitors immunotherapy iron chelation |
| title | Osteosarcoma in Children: Not Only Chemotherapy |
| title_full | Osteosarcoma in Children: Not Only Chemotherapy |
| title_fullStr | Osteosarcoma in Children: Not Only Chemotherapy |
| title_full_unstemmed | Osteosarcoma in Children: Not Only Chemotherapy |
| title_short | Osteosarcoma in Children: Not Only Chemotherapy |
| title_sort | osteosarcoma in children not only chemotherapy |
| topic | osteosarcoma chemoresistance therapy proteasome inhibitors immunotherapy iron chelation |
| url | https://www.mdpi.com/1424-8247/14/9/923 |
| work_keys_str_mv | AT mauraargenziano osteosarcomainchildrennotonlychemotherapy AT chiaratortora osteosarcomainchildrennotonlychemotherapy AT elvirapota osteosarcomainchildrennotonlychemotherapy AT alessandradipaola osteosarcomainchildrennotonlychemotherapy AT martinadimartino osteosarcomainchildrennotonlychemotherapy AT caterinadileva osteosarcomainchildrennotonlychemotherapy AT danieladipinto osteosarcomainchildrennotonlychemotherapy AT francescarossi osteosarcomainchildrennotonlychemotherapy |